175 related articles for article (PubMed ID: 16946010)
1. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis.
Ciampi R; Nikiforov YE
Endocrinology; 2007 Mar; 148(3):936-41. PubMed ID: 16946010
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation patterns in papillary thyroid cancer are distinct based on histological subtype and tumor genotype.
Ellis RJ; Wang Y; Stevenson HS; Boufraqech M; Patel D; Nilubol N; Davis S; Edelman DC; Merino MJ; He M; Zhang L; Meltzer PS; Kebebew E
J Clin Endocrinol Metab; 2014 Feb; 99(2):E329-37. PubMed ID: 24423287
[TBL] [Abstract][Full Text] [Related]
3. BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population.
Batool M; Khan NU; Khan H; Almutairi MH; Ali I; Adams BD
Mol Biol Rep; 2024 Apr; 51(1):502. PubMed ID: 38598020
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
[TBL] [Abstract][Full Text] [Related]
5. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Gainor JF; Curigliano G; Kim DW; Lee DH; Besse B; Baik CS; Doebele RC; Cassier PA; Lopes G; Tan DSW; Garralda E; Paz-Ares LG; Cho BC; Gadgeel SM; Thomas M; Liu SV; Taylor MH; Mansfield AS; Zhu VW; Clifford C; Zhang H; Palmer M; Green J; Turner CD; Subbiah V
Lancet Oncol; 2021 Jul; 22(7):959-969. PubMed ID: 34118197
[TBL] [Abstract][Full Text] [Related]
6. The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study.
Chen JY; Huang NS; Wei WJ; Hu JQ; Cao YM; Shen Q; Lu ZW; Wang YL; Wang Y; Ji QH
Ann Surg Oncol; 2023 Nov; 30(12):7172-7180. PubMed ID: 37543550
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of cancers derived from thyroid follicular cells.
Fagin JA; Krishnamoorthy GP; Landa I
Nat Rev Cancer; 2023 Sep; 23(9):631-650. PubMed ID: 37438605
[TBL] [Abstract][Full Text] [Related]
8. Current perspectives on the management of patients with advanced
Elisei R; Grande E; Kreissl MC; Leboulleux S; Puri T; Fasnacht N; Capdevila J
Front Oncol; 2023; 13():1141314. PubMed ID: 37207147
[TBL] [Abstract][Full Text] [Related]
9. The role of molecular testing in pancreatic cancer.
Zhen DB; Safyan RA; Konick EQ; Nguyen R; Prichard CC; Chiorean EG
Therap Adv Gastroenterol; 2023; 16():17562848231171456. PubMed ID: 37197396
[TBL] [Abstract][Full Text] [Related]
10. ARROW: pralsetinib hits target across cancers.
Killock D
Nat Rev Clin Oncol; 2022 Oct; 19(10):615. PubMed ID: 35999290
[No Abstract] [Full Text] [Related]
11. Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.
Griesinger F; Curigliano G; Thomas M; Subbiah V; Baik CS; Tan DSW; Lee DH; Misch D; Garralda E; Kim DW; van der Wekken AJ; Gainor JF; Paz-Ares L; Liu SV; Kalemkerian GP; Houvras Y; Bowles DW; Mansfield AS; Lin JJ; Smoljanovic V; Rahman A; Kong S; Zalutskaya A; Louie-Gao M; Boral AL; Mazières J
Ann Oncol; 2022 Nov; 33(11):1168-1178. PubMed ID: 35973665
[TBL] [Abstract][Full Text] [Related]
12. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
Syed YY
Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
[TBL] [Abstract][Full Text] [Related]
13. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
Nguyen L; Monestime S
Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
[TBL] [Abstract][Full Text] [Related]
14. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study.
Subbiah V; Hu MI; Wirth LJ; Schuler M; Mansfield AS; Curigliano G; Brose MS; Zhu VW; Leboulleux S; Bowles DW; Baik CS; Adkins D; Keam B; Matos I; Garralda E; Gainor JF; Lopes G; Lin CC; Godbert Y; Sarker D; Miller SG; Clifford C; Zhang H; Turner CD; Taylor MH
Lancet Diabetes Endocrinol; 2021 Aug; 9(8):491-501. PubMed ID: 34118198
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Selpercatinib in
Drilon A; Oxnard GR; Tan DSW; Loong HHF; Johnson M; Gainor J; McCoach CE; Gautschi O; Besse B; Cho BC; Peled N; Weiss J; Kim YJ; Ohe Y; Nishio M; Park K; Patel J; Seto T; Sakamoto T; Rosen E; Shah MH; Barlesi F; Cassier PA; Bazhenova L; De Braud F; Garralda E; Velcheti V; Satouchi M; Ohashi K; Pennell NA; Reckamp KL; Dy GK; Wolf J; Solomon B; Falchook G; Ebata K; Nguyen M; Nair B; Zhu EY; Yang L; Huang X; Olek E; Rothenberg SM; Goto K; Subbiah V
N Engl J Med; 2020 Aug; 383(9):813-824. PubMed ID: 32846060
[TBL] [Abstract][Full Text] [Related]
16. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
Hong DS; DuBois SG; Kummar S; Farago AF; Albert CM; Rohrberg KS; van Tilburg CM; Nagasubramanian R; Berlin JD; Federman N; Mascarenhas L; Geoerger B; Dowlati A; Pappo AS; Bielack S; Doz F; McDermott R; Patel JD; Schilder RJ; Tahara M; Pfister SM; Witt O; Ladanyi M; Rudzinski ER; Nanda S; Childs BH; Laetsch TW; Hyman DM; Drilon A
Lancet Oncol; 2020 Apr; 21(4):531-540. PubMed ID: 32105622
[TBL] [Abstract][Full Text] [Related]
17.
Kato S; Subbiah V; Marchlik E; Elkin SK; Carter JL; Kurzrock R
Clin Cancer Res; 2017 Apr; 23(8):1988-1997. PubMed ID: 27683183
[No Abstract] [Full Text] [Related]
18. Integrated genomic characterization of papillary thyroid carcinoma.
Cancer Genome Atlas Research Network
Cell; 2014 Oct; 159(3):676-90. PubMed ID: 25417114
[TBL] [Abstract][Full Text] [Related]
19. Progress in molecular-based management of differentiated thyroid cancer.
Xing M; Haugen BR; Schlumberger M
Lancet; 2013 Mar; 381(9871):1058-69. PubMed ID: 23668556
[TBL] [Abstract][Full Text] [Related]
20. Molecular genetics and diagnosis of thyroid cancer.
Nikiforov YE; Nikiforova MN
Nat Rev Endocrinol; 2011 Aug; 7(10):569-80. PubMed ID: 21878896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]